Home » Stocks » CYAD

Celyad S.A. (CYAD)

Stock Price: $5.67 USD 0.01 (0.18%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 92.41M
Revenue (ttm) 6,098
Net Income (ttm) -20.98M
Shares Out 15.01M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.67
Previous Close $5.66
Change ($) 0.01
Change (%) 0.18%
Day's Open 5.79
Day's Range 5.50 - 5.82
Day's Volume 149,248
52-Week Range 5.27 - 13.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric an...

3 days ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

2 weeks ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

1 month ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, March 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

1 month ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, March 24, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

1 month ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

1 month ago - Business Wire

MONT-SAINT-GUIBERT, Belgium, March 01, 2021 (GLOBE NEWSWIRE) -- Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discover...

2 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

2 months ago - Business Wire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

3 months ago - Business Wire

MONT-SAINT-GUIBERT, Belgium, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

3 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

3 months ago - GlobeNewsWire

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other stocks mentioned: ACRS, GRTS, MRUS, NERV, TENX
3 months ago - Benzinga

MONT-SAINT-GUIBERT, Belgium, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

3 months ago - GlobeNewsWire

Celyad Oncology's technology, although still under development, has exciting possibilities, including the simplification of design and development of future therapy candidates, which could make therapie...

3 months ago - Seeking Alpha

MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

3 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developme...

4 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

4 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

4 months ago - Business Wire

MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

4 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

5 months ago - Business Wire

MONT-SAINT-GUIBERT, Belgium, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

5 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

5 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on ...

5 months ago - Business Wire

MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

5 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

6 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeri...

7 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

7 months ago - Business Wire

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

7 months ago - Business Wire

MONT-SAINT-GUIBERT, Belgium, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeri...

7 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric...

8 months ago - GlobeNewsWire

Celyad Oncology's (CYAD) CEO Filippo Petti on First Half 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

MONT-SAINT-GUIBERT, Belgium, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric...

9 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric...

9 months ago - GlobeNewsWire

Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.

9 months ago - Zacks Investment Research

MONT-SAINT-GUIBERT, Belgium, July 14, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric...

9 months ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, June 10, 2020 (GLOBE NEWSWIRE) -- Celyad SA (Euronext & Nasdaq: CYAD), clinical-stage biotechnology company focused on the discovery and development of chimeric antigen re...

10 months ago - GlobeNewsWire

Celyad's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma

11 months ago - Seeking Alpha

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

Other stocks mentioned: DXCM, HOLX, NCNA, TDOC
11 months ago - Zacks Investment Research

Celyad SA (CYAD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11 months ago - Zacks Investment Research

MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cel...

1 year ago - GlobeNewsWire

- Company postpones Extraordinary General Meeting from May 5, 2020 to June 8, 2020 - Company postpones Extraordinary General Meeting from May 5, 2020 to June 8, 2020

1 year ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for April 20th

Other stocks mentioned: ARAV, BCRX, MRSN
1 year ago - Zacks Investment Research

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Celyad SA (CYAD) CEO Filippo Petti on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

MONT-SAINT-GUIBERT, Belgium, March 02, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T c...

1 year ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T ce...

1 year ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T ce...

1 year ago - GlobeNewsWire

MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T ce...

1 year ago - GlobeNewsWire

Celyad SA (CYAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

MONT-SAINT-GUIBERT, Belgium, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T ce...

1 year ago - GlobeNewsWire

About CYAD

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T thera... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Filippo Petti
Employees
87
Stock Exchange
NASDAQ
Ticker Symbol
CYAD
Full Company Profile

Financial Performance

In 2020, Celyad's revenue was 5,000, a decrease of -16.67% compared to the previous year's 6,000. Losses were -17.20 million, -39.91% less than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Celyad stock is "Strong Buy." The 12-month stock price forecast is 19.10, which is an increase of 236.86% from the latest price.

Price Target
$19.10
(236.86% upside)
Analyst Consensus: Strong Buy